MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)

MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

Oct. 19, 2007

By Donna Young

MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026